Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 12,665 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period A Clear all

Conditions: Insomnia
Interventions: Relaxation Acupressure, Stimulating Acupressure; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions: Diabetes Knowledge/Information, Motivation/Behavioral Skills, Combined Intervention, Usual Care; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Epilepsy
Interventions: ataluren, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 12 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Interventions: Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 29 Days to 17 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more

Conditions: Wheezing, Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more

Conditions: Healthy Participants
Interventions: PF-06651600; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Hollywood, Florida • Saint Paul, Minnesota

Conditions: Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions: I004, NovoLog; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Breast Cancer
Interventions: exemestane; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Small Cell Lung Cancer, Lung Cancer, Relapsed Small Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab, Dendritic Cell based p53 Vaccine; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy Volunteers
Interventions: Deflazacort and rifampin, Deflazacort and Clarithromycin; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: E2006 2.5 mg, E2006 10 mg, E2006 25 mg, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: repaglinide, metformin, repaglinide and metformin combination tablet; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Anxiety
Interventions: CES treatment using Alpha-Stim technology, Shame CES Treatment; Device
Lead sponsor: Wyndhurst Counseling Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Lynchburg, Virginia

Conditions: Noninvasive Ventilation, Low Birth Weight
Interventions: Neurally Adjusted Ventilatory Assist, Nasal Intermittent Positive Pressure Ventilation; Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Diffuse Apneic Oxygenation
Interventions: Oxygen, Standard of care; Other
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Breastfeeding
Interventions: "Breastfeeding at AU" Smartphone Application; Other
Lead sponsor: Augusta University; Other
Eligibility: Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Arthritis, Rheumatoid
Interventions: Cannabichromene; Drug
Lead sponsor: Crystal Lederhos Smith; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2030
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Autism, Autism Spectrum Disorder
Interventions: Diphenhydramine, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Prevention, Wellbeing
Interventions: INSPIRE Initiative, Standard of Care; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: New York, New York

Conditions: Healthy Volunteer
Interventions: Alectinib, Esomeprazole, High Fat and Calorie Meal, Standard Meal; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Health Adult Subjects
Interventions: Omaveloxolone, Moxifloxacin; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity, Weight Loss
Interventions: Maintenance program, Phone coaching; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 72 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Fragile X-associated Tremor/Ataxia Syndrome
Interventions: Allopregnanolone; Drug
Lead sponsor: Randi J. Hagerman, MD; Other
Eligibility: 50 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Pain
Interventions: ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product); Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Bend, Wisconsin

Search by objective public record fields.

Acupressure for Insomnia

Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

Use of Alpha-Stim Cranial-electrotherapy Stimulation (CES) in the Treatment of Anxiety

Noninvasive NAVA Versus NIPPV in Low Birthweight Premature Infants

EmergeNcy Department Apneic Oxygenation Versus Usual Care During Rapid Sequence Intubation

A Technological Approach to Improved Breastfeeding Rates and Self-Efficacy

Cannabichromene Safety in Rheumatoid Arthritis

Trial of Diphenhydramine for Sleep in Children With Autism

Initiative for Chinese Sex Workers to Promote Wellbeing and Improve HIV Prevention by Reducing intersEctional Stigma

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

A TQTc Study for Omaveloxolone

Phone Coaching for Weight Loss Maintenance

Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects